Newsroom

Newsroom

Measurement of Immune Infiltration in ER, PR, HER2 IHC Subtypes Reveals Different Populations That May Benefit from Immunotherapy

Literature
Read More

MultiOmyx™: A multiplexed immunofluorescent assay capable of profiling protein expression and phosphorylation, in combination with next-generation sequencing from a single FFPE tissue section

Literature
Read More

NeoGenomics Schedules its Q1 2015 Earnings Release for April 28, 2015

Press Release
Read More

ALK positivity rate is highly dependent on patient age

Literature
Read More

Genetic array analysis of follicular dendritic cell carcinoma

Literature
Read More

Synonymous polymorphisms in HOXB13 as a predictive factor for prostate cancer

Literature
Read More

NeoGenomics Reports Record Revenue of $25.0 Million, Adjusted EBITDA of $2.8 MM and Net Income of $0.02 per Share for the Fourth Quarter 2014

Press Release
Read More

NeoGenomics Schedules its Q4 2014 and Full Year 2014 Earnings Release for February 24, 2015

Press Release
Read More

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients